EX-99.1 2 thrm-ex99_1.htm EX-99.1 EX-99.1

 

img17760854_0.jpg 

img17760854_1.jpg 

 

Exhibit 99.1

Gentherm Reports 2022 Third Quarter Results

 

Announces Record Quarterly Revenue, including Record Organic Quarterly Revenue

Secured the First Combined Award for Thermal and Pneumatic Comfort

Maintains Total Company 2022 Guidance

 

NORTHVILLE, Michigan, November 2, 2022 /Global Newswire/ - Gentherm (NASDAQ:THRM), a global market leader of innovative thermal management and pneumatic comfort technologies, today announced its financial results for the third quarter ended September 30, 2022.

Third Quarter Highlights

Product revenues of $333.0 million increased 36.8% from $243.4 million in the 2021 third quarter, resulting in the highest quarterly revenue in company history, as well as the highest quarterly organic revenue of $290.4 million excluding revenues from the acquired businesses
o
Excluding the impact of foreign currency translation, product revenues increased 44.4% year over year
o
Excluding the impact of foreign currency translation and acquisitions, product revenues increased 27.0% year over year
GAAP diluted earnings per share was $0.29 as compared to $0.47 in the prior-year period
Adjusted earnings per share (see table herein) was $0.70 as compared to $0.51 in the prior-year period
Secured automotive new business awards totaling $430 million
Announced the first combined award for thermal and pneumatic comfort for one of the largest global electric vehicle (EV) manufacturers

Phil Eyler, the Company's President and CEO, said “Our third quarter results validate the effectiveness of our focused growth strategy and demonstrate our unique position to capitalize on industry megatrends in the mid and long term. As we mark the completion of the initial quarter since closing the acquisition of Alfmeier, we and our customers have already begun benefitting from Gentherm’s expanded value proposition. Demand for our thermal and pneumatic massage and lumbar comfort solutions, especially in the electric vehicle (EV) market, continues to be strong – evidenced by the milestone achievements of our third quarter. First, we won our inaugural combined award for thermal and pneumatic comfort with one of the largest global EV manufacturers. Second, we recently announced that the 2024 Cadillac CELESTIQ will be the first-to-market vehicle to feature Gentherm’s ClimateSense® four-zone microclimate system as standard equipment. These awards underscore the growing traction of our innovative solutions.”

“I am extremely proud of the global Gentherm team for driving ground-breaking innovation, outperforming light vehicle production, stringently managing costs and delivering record quarterly revenue despite a challenging industry backdrop” continued Eyler.

2022 Third Quarter Financial Review

Product revenues of $333.0 million increased $89.6 million, or 36.8%, in the third quarter of 2022 as compared to the prior-year period. Excluding the impact of foreign currency translation, product revenues increased 44.4% year over year. On a comparable basis, adjusting for acquisitions and foreign currency translation, product revenues increased 27.0% year over year.

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

The company added $41.3 million in revenue resulting from the acquisition of Alfmeier effective August 1, 2022. Alfmeier grew 16.9% from the comparable prior-year two-month period, excluding the impact of foreign currency translation.

Automotive revenues increased 38.4% year over year, driven by contribution from the acquisition of Alfmeier as well as growth in Steering Wheel Heaters, Climate Controlled Seat, Seat Heaters, Battery Performance Solutions, and Other Automotive. Adjusting for foreign currency translation and the Alfmeier acquisition, Automotive revenues increased 28.5% year over year. According to S&P Global Mobility, actual light vehicle production increased by 25.8% when compared to the third quarter of 2021 in the Company’s key markets of North America, Europe, China, Japan, and Korea.

Gentherm Medical revenue increased 0.5% year over year, 4.1% excluding the impact of foreign currency translation, driven by a $1.2 million contribution from the acquisition of Dacheng Medical.

See the “Revenue by Product Category” table included below for additional detail.

The gross margin rate decreased to 24.1% in the current-year period versus 28.5% in the prior-year period, primarily as a result of wage and material inflation, the industry-wide supply chain disruptions, the acquired Alfmeier business having a lower gross margin rate relative to the Company’s organic business, as well as the negative impact from foreign currency translation. These were partially offset by fixed cost leverage from higher unit volume and cost recoveries from customers.

Net research and development expenses of $22.7 million in the third quarter of 2022 increased $2.1 million, or 10.1%, primarily as a result of the additional expenses from the Alfmeier business and increased investments in ClimateSense and battery performance solutions.

Selling, general and administrative (SG&A) expenses of $34.9 million in the third quarter of 2022 increased $7.5 million, or 27.5%, versus the prior-year period. The year-over-year increase was primarily driven by $7.5 million of expenses associated with the Alfmeier and Dacheng acquisitions and additional expenses from the acquired businesses, partially offset by lower incentive compensation.

Acquisition expenses of $11.3 million in the current-year period were $11.3 million higher than the prior-year period as a result of expenses associated with the Alfmeier and Dacheng acquisitions including previously noted SG&A expenses and $3.8 million realized foreign currency loss. The Company incurred minimal restructuring expenses in the current-year period, compared to $0.7 million in the prior-year period.

As described more fully in the table included below, “Reconciliation of Net Income to Adjusted EBITDA,” the Company recorded Adjusted EBITDA of $43.2 million during the third quarter of 2022 compared to $30.5 million in the prior year, a year-over-year increase of $12.7 million or 41.7%.

Income tax expense in the 2022 third quarter was $5.8 million, as compared with $4.6 million in the prior-year period. The effective tax rate was 37.1% for the current-year quarter.

GAAP diluted earnings per share for the third quarter of 2022 was $0.29 compared with $0.47 for the prior-year period. Adjusted diluted earnings per share, excluding acquisition expenses, unrealized currency loss, non-cash purchase accounting impact, and other impacts (see table herein), was $0.70. Adjusted diluted earnings per share in the prior-year period was $0.51.

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

Guidance

The Company maintains its total company full-year 2022 guidance but updates acquisition assumptions that were initially provided in its second quarter 2022 earnings release on August 2, 2022:

Product revenues between $1.15 billion and $1.25 billion, based on the current forecast of customer orders, supply chain constraints, estimated recovery of industry-wide semiconductor supply, light vehicle production in the Company’s key markets growing at a low single-digit rate in 2022 versus 2021 and current foreign exchange rates
Adjusted EBITDA margin between 10% and 12% of product revenues
Assumes approximately $100 million of product revenues and low single-digit EBITDA margin rate from the acquisitions
Full-year effective tax rate between 29% and 31%
Capital expenditures between $50 million and $60 million

Conference Call

 

As previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-877-300-8521 (callers in the U.S.) or +1-412-317-6026 (callers outside this U.S.). The passcode for the live call is 10172220.

A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

A telephonic replay will be available approximately two hours after the call until 11:59 pm Eastern Time on November 16, 2022. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 10172220.

 

 

Investor Relations Contact
Yijing Brentano

investors@gentherm.com
(248) 308-1702

 

Media Contact

Melissa Fischer

media@gentherm.com

248.289.9702

About Gentherm

 

Gentherm (NASDAQ:THRM) is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, valve system technologies, and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets.

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

Gentherm has approximately 13,000 employees in facilities in the United States, Germany, China, Czech Republic, Hungary, Japan, Malta, Mexico, North Macedonia, South Korea, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.

 

Forward-Looking Statements

 

Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this release are made as of the date hereof or as of the date specified herein and are based on management's reasonable expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause actual results or performance to differ materially from that described in or indicated by the forward-looking statements, including that:

 

the current supply-constrained environment the Company is facing involving component shortages, manufacturing disruptions, logistics challenges and inflationary pressures, and any future material delays or inflationary pressures in the supply chain of the Company or the automotive original equipment manufacturers or first tier suppliers supplied by the Company;
the period of sustained price increases for various material components and shipping costs currently experienced in the automotive industry, which may continue for longer than the Company expects;
risks relating to the Company’s recent acquisitions of Alfmeier and Dacheng Medical (the “Acquisitions”), including: the Company’s increased debt leverage following the closing of the Acquisitions; risks inherent in the achievement of expected financial results, growth prospects and cost synergies for each of the Acquisitions and the timing thereof; and integration risks;
the impact of industry or consumer behaviors on future automotive vehicle production and the Company’s strategy to develop and sell products tailored to evolving market demands, including the development and use of autonomous and electric vehicles and increasing use of car- and ride-sharing and on-demand transportation as a service, as well as related regulations;
labor shortages, wage inflation and work stoppages impacting the Company, its suppliers or customers;
the COVID-19 pandemic and its direct and indirect adverse impacts on the automobile and medical industries and global economy, which had, and are likely to continue to have, an adverse effect on, among other things, the Company’s results of operations, financial condition, cash flows, liquidity, business operations, and stock price;
borrowing availability under the Company’s revolving credit facility;
the Company’s failure to be in compliance with covenants under its debt agreements, which could result in the amounts outstanding thereunder being accelerated and becoming immediately due and payable;
the Company’s ability to obtain additional financing by accessing the capital markets, which may not be available on acceptable terms or at all;
the macroeconomic environment, including its impact on the automotive industry, which is cyclical;
any significant declines in automobile production;
market acceptance of the Company’s existing or new products, and new or improved competing products developed by competitors with greater resources;
shifting customer preferences, including due to the evolving use of automobiles and technology;

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

the Company’s ability to project future sales volumes, based on which the Company manages its business;
reductions in new business awards due to the macroeconomic environment, COVID-19 and related uncertainties;
the Company’s ability to convert new business awards into product revenues;
the loss, material reduction in sales from or the insolvency of any of the Company’s key customers, including due to M&A or other market consolidation of OEMs and Tier 1s;
the loss of any key suppliers;
the impact of price downs in the ordinary course, or additional increased pricing pressures from the Company’s customers;
the feasibility of Company’s development of new products on a timely, cost effective basis, or at all;
security breaches and other disruptions to the Company’s IT systems;
changes in free trade agreements or the implementation of additional tariffs, and the Company’s ability to pass-through tariff costs;
unfavorable changes to currency exchange rates and interest rates;
the Company’s ability to protect its intellectual property in certain jurisdictions;
the Company’s ability to effectively implement restructuring and other cost-savings measures or realize the full amount of estimated savings;
compliance with, and increased costs related to, domestic and international regulations, including potential climate change regulations;
the Ukraine-Russia conflict, which has led to and could lead to further challenges and disruptions in our manufacturing operations in our Ukraine facility and further global economic sanctions and market disruptions, including significant volatility in commodity prices, credit and capital markets, supply constraints of natural gas, as well as supply chain interruptions;
changes in government leadership and laws, political instability and economic tensions between governments, including as a result of the ongoing Ukraine-Russian conflict; and
severe weather conditions and natural disasters and any resultant disruptions on the supply or production of goods or services or customer demands.

 

The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent SEC filings, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this release does not include the impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s future business and financial results.

 

Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

 

 

 

 

 

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Product revenues

 

$

332,962

 

 

$

243,384

 

 

$

861,334

 

 

$

797,924

 

Cost of sales

 

 

252,610

 

 

 

173,997

 

 

 

657,492

 

 

 

561,655

 

Gross margin

 

 

80,352

 

 

 

69,387

 

 

 

203,842

 

 

 

236,269

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Net research and development expenses

 

 

22,666

 

 

 

20,590

 

 

 

62,425

 

 

 

56,420

 

Selling, general and administrative expenses

 

 

34,859

 

 

 

27,344

 

 

 

96,109

 

 

 

83,093

 

Restructuring expenses

 

 

6

 

 

 

749

 

 

 

561

 

 

 

3,631

 

Total operating expenses

 

 

57,531

 

 

 

48,683

 

 

 

159,095

 

 

 

143,144

 

Operating income

 

 

22,821

 

 

 

20,704

 

 

 

44,747

 

 

 

93,125

 

Interest expense, net

 

 

714

 

 

 

(515

)

 

 

(1,285

)

 

 

(2,184

)

Foreign currency (loss) gain

 

 

(8,285

)

 

 

133

 

 

 

(1,516

)

 

 

391

 

Other income

 

 

361

 

 

 

10

 

 

 

698

 

 

 

13

 

Earnings before income tax

 

 

15,611

 

 

 

20,332

 

 

 

42,644

 

 

 

91,345

 

Income tax expense

 

 

5,784

 

 

 

4,646

 

 

 

13,998

 

 

 

17,959

 

Net income

 

$

9,827

 

 

$

15,686

 

 

$

28,646

 

 

$

73,386

 

Basic earnings per share

 

$

0.30

 

 

$

0.47

 

 

$

0.87

 

 

$

2.22

 

Diluted earnings per share

 

$

0.29

 

 

$

0.47

 

 

$

0.86

 

 

$

2.19

 

Weighted average number of shares – basic

 

 

33,162

 

 

 

33,178

 

 

 

33,106

 

 

 

33,075

 

Weighted average number of shares – diluted

 

 

33,470

 

 

 

33,609

 

 

 

33,460

 

 

 

33,489

 

 

 

 

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

GENTHERM INCORPORATED

REVENUE BY PRODUCT CATEGORY AND RECONCILIATION OF FOREIGN CURRENCY TRANSLATION IMPACT

(In thousands)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

% Change

 

 

2022

 

 

2021

 

% Change

 

Climate Control Seat

 

$

112,059

 

 

$

89,991

 

 

24.5

%

 

$

311,281

 

 

$

297,393

 

 

4.7

%

Seat Heaters

 

 

75,568

 

 

 

61,516

 

 

22.8

%

 

 

210,367

 

 

 

208,101

 

 

1.1

%

Steering Wheel Heaters

 

 

31,482

 

 

 

24,578

 

 

28.1

%

 

 

89,169

 

 

 

80,139

 

 

11.3

%

Automotive Cables

 

 

18,338

 

 

 

19,465

 

 

(5.8

)%

 

 

59,662

 

 

 

66,686

 

 

(10.5

)%

Battery Performance Solutions

 

 

20,331

 

 

 

16,928

 

 

20.1

%

 

 

55,395

 

 

 

52,265

 

 

6.0

%

Electronics

 

 

12,083

 

 

 

11,567

 

 

4.5

%

 

 

33,190

 

 

 

41,324

 

 

(19.7

)%

Lumbar and Massage Comfort Solutions (a)

 

 

22,740

 

 

 

 

 

100.0

%

 

 

22,740

 

 

 

 

 

100.0

%

Valve System Technologies (a)

 

 

18,542

 

 

 

 

 

100.0

%

 

 

18,542

 

 

 

 

 

100.0

%

Other Automotive

 

 

11,412

 

 

 

8,983

 

 

27.0

%

 

 

29,224

 

 

 

21,595

 

 

35.3

%

Subtotal Automotive segment

 

 

322,555

 

 

 

233,028

 

 

38.4

%

 

 

829,570

 

 

 

767,503

 

 

8.1

%

Medical segment (b)

 

 

10,407

 

 

 

10,356

 

 

0.5

%

 

 

31,764

 

 

 

30,421

 

 

4.4

%

Total Company

 

$

332,962

 

 

$

243,384

 

 

36.8

%

 

$

861,334

 

 

$

797,924

 

 

7.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation impact (c)

 

 

(18,438

)

 

 

 

 

 

 

 

(38,609

)

 

 

 

 

 

Total Company, excluding foreign
currency translation impact

 

$

351,400

 

 

$

243,384

 

 

44.4

%

 

$

899,943

 

 

$

797,924

 

 

12.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a) Represents product revenues from Alfmeier since the acquisition date of August 1, 2022.

 

(b) Includes product revenues of $1,234 from Dacheng since the acquisition date of July 13, 2022.

 

(c) Foreign currency translation impacts for the Automotive segment and Medical segment were $(18,068) and $(370), respectively, for the three months ended September 30, 2022.

 

 

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

GENTHERM INCORPORATED

RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

(In thousands)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net income

 

$

9,827

 

 

$

15,686

 

 

$

28,646

 

 

$

73,386

 

Add back:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

11,774

 

 

 

9,859

 

 

 

30,259

 

 

 

29,182

 

Income tax expense

 

 

5,784

 

 

 

4,646

 

 

 

13,998

 

 

 

17,959

 

Interest (income) expense, net (a)

 

 

(714

)

 

 

515

 

 

 

1,285

 

 

 

2,184

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring expense

 

 

6

 

 

 

749

 

 

 

561

 

 

 

3,631

 

Unrealized currency loss (gain)

 

 

5,308

 

 

 

(1,039

)

 

 

(1,032

)

 

 

(1,345

)

Acquisition expenses (b) (c)

 

 

11,349

 

 

 

65

 

 

 

18,357

 

 

 

1,023

 

Other

 

 

(157

)

 

 

 

 

 

(483

)

 

 

 

Adjusted EBITDA

 

$

43,177

 

 

$

30,481

 

 

$

91,591

 

 

$

126,020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenues

 

$

332,962

 

 

$

243,384

 

 

$

861,334

 

 

$

797,924

 

Adjusted EBITDA %

 

 

13.0

%

 

 

12.5

%

 

 

10.6

%

 

 

15.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

(a) Includes $3,191 and $2,498 of interest income for the three and nine months ended September 30, 2022, respectively, related to mark-to-market adjustment of our floating-to-fixed interest rate swap agreement with a notional amount of $100,000.

 

(b) Includes realized foreign currency loss of $3,806 for the three and nine months ended September 30, 2022, related to foreign currency forward contracts used to hedge the foreign currency risk associated with the forecasted purchase of Alfmeier.

 

(c) Includes compensation expense of $1,091 for the three and nine months ended September 30, 2022, related to accruals for Dacheng contingent payments that were negotiated with seller as part of the Dacheng acquisition. These contingent payments are expected to be paid upon the achievement of certain performance metrics and continued employment of the former majority shareholder of Dacheng.

 

 

Use of Non-GAAP Financial Measures

 

In addition to the results reported in accordance with GAAP throughout this release, the Company has provided here or elsewhere information regarding adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”), Adjusted EBITDA margin, adjusted earnings per share (“Adjusted earnings per share” or “Adjusted EPS”), free cash flow, Net Debt, organic revenue, revenue excluding acquired businesses and foreign currency translation, revenue excluding foreign currency translation, and gross margin rate excluding acquired businesses, each a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Adjusted EBITDA margin as Adjusted EBITDA divided by product revenues. The Company defines Adjusted EPS as earnings adjusted by gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Free Cash Flow as Net cash (used in) provided by operating activities less Purchases of property and equipment. The Company defines Net Debt as the principal amount of all Consolidated Funded Indebtedness (as defined in the Credit Agreement) less cash and cash equivalents. The Company defines organic revenue as revenue, excluding revenue from acquired businesses. Note that in recent prior periods, the Company used organic revenue instead to be revenue excluding foreign currency translation (see below). The Company defines revenue

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

excluding acquired businesses and foreign currency translation as revenue, excluding the revenue from acquired businesses and the estimated effects of foreign currency exchange on revenue by translating actual revenue using the prior period foreign currency exchange rates. The Company defines revenue excluding foreign currency translation as revenue, excluding the estimated effects of foreign currency exchange on revenue by translating actual revenue using the prior period foreign currency exchange rates.

 

The Company’s reconciliations are included in this release or can be found in the supplemental materials furnished as Exhibit 99.2 to the Company’s Form 8-K dated November 2, 2022.

 

In evaluating its business, the Company considers and uses Free Cash Flow and Net Debt as supplemental measures of its liquidity and the other non-GAAP financial measures as supplemental measures of its operating performance. Management provides such non-GAAP financial measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis by excluding matters not indicative of the Company’s ongoing operating or liquidity results. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur revenues, expenses, and cash and non-cash obligations that are the same as or similar to some of the adjustments in our presentation of non-GAAP financial measures. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. There also can be no assurance that we will not modify the presentation of our non-GAAP financial measures in the future, and any such modification may be material. Other companies in our industry may define and calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance or liquidity, investors should not consider these non-GAAP measures in isolation, or as a substitute for net income, revenue or other consolidated income statement or cash flow statement data prepared in accordance with GAAP.

 

Non-GAAP measures referenced in this release and other public communications may include estimates of future Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EPS. Such forward-looking non-GAAP measures may differ significantly from the corresponding GAAP measures, due to depreciation and amortization, tax expense, and/or interest expense, some or all of which management has not quantified for the future periods.

 

 

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

GENTHERM INCORPORATED

ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE

(In thousands, except per share data)

(Unaudited)

 

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net income

 

$

9,827

 

 

$

15,686

 

 

$

28,646

 

 

$

73,386

 

Non-cash purchase accounting impact

 

 

2,842

 

 

 

2,141

 

 

 

6,426

 

 

 

6,241

 

Restructuring expenses

 

 

6

 

 

 

749

 

 

 

561

 

 

 

3,631

 

Unrealized currency loss (gain)

 

 

5,308

 

 

 

(1,039

)

 

 

(1,032

)

 

 

(1,345

)

Acquisition expenses (a) (b)

 

 

11,349

 

 

 

65

 

 

 

18,357

 

 

 

1,023

 

Other

 

 

(157

)

 

 

 

 

 

(483

)

 

 

 

Tax effect of above

 

 

(5,822

)

 

 

(566

)

 

 

(7,020

)

 

 

(2,557

)

Adjusted net income

 

$

23,353

 

 

$

17,036

 

 

$

45,455

 

 

$

80,379

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

33,162

 

 

 

33,178

 

 

 

33,106

 

 

 

33,075

 

Diluted

 

 

33,470

 

 

 

33,609

 

 

 

33,460

 

 

 

33,489

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share, as reported:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.30

 

 

$

0.47

 

 

$

0.87

 

 

$

2.22

 

Diluted

 

$

0.29

 

 

$

0.47

 

 

$

0.86

 

 

$

2.19

 

Adjusted earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.70

 

 

$

0.51

 

 

$

1.37

 

 

$

2.43

 

Diluted

 

$

0.70

 

 

$

0.51

 

 

$

1.36

 

 

$

2.40

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a) Includes realized foreign currency loss of $3,806 for the three and nine months ended September 30, 2022, related to foreign currency forward contracts used to hedge the foreign currency risk associated with the forecasted purchase of Alfmeier.

 

(b) Includes compensation expense of $1,091 for the three and nine months ended September 30, 2022, related to accruals for Dacheng contingent payments that were negotiated with seller as part of the Dacheng acquisition. These contingent payments are expected to be paid upon the achievement of certain performance metrics and continued employment of the former majority shareholder of Dacheng.

 

 

 

 

 

 

 

 

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

 

 

 

September 30, 2022

 

 

December 31, 2021

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

139,163

 

 

$

190,606

 

Accounts receivable, net

 

 

248,570

 

 

 

182,987

 

Inventory:

 

 

 

 

 

 

Raw materials

 

 

154,273

 

 

 

96,426

 

Work in process

 

 

17,157

 

 

 

9,495

 

Finished goods

 

 

62,465

 

 

 

53,556

 

Inventory, net

 

 

233,895

 

 

 

159,477

 

Other current assets

 

 

84,344

 

 

 

32,775

 

Total current assets

 

 

705,972

 

 

 

565,845

 

Property and equipment, net

 

 

228,056

 

 

 

155,270

 

Goodwill

 

 

125,273

 

 

 

66,033

 

Other intangible assets, net

 

 

68,639

 

 

 

37,554

 

Operating lease right-of-use assets

 

 

30,214

 

 

 

24,387

 

Deferred income tax assets

 

 

66,322

 

 

 

69,630

 

Other non-current assets

 

 

16,857

 

 

 

16,624

 

Total assets

 

$

1,241,333

 

 

$

935,343

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

Accounts payable

 

$

208,338

 

 

$

122,727

 

Current lease liabilities

 

 

7,448

 

 

 

5,669

 

Current maturities of long-term debt

 

 

3,540

 

 

 

2,500

 

Other current liabilities

 

 

100,898

 

 

 

82,193

 

Total current liabilities

 

 

320,224

 

 

 

213,089

 

Long-term debt, less current maturities

 

 

232,000

 

 

 

36,250

 

Non-current lease liabilities

 

 

22,013

 

 

 

19,789

 

Pension benefit obligation

 

 

5,850

 

 

 

6,832

 

Other non-current liabilities

 

 

37,157

 

 

 

5,577

 

Total liabilities

 

$

617,244

 

 

$

281,537

 

Shareholders’ equity:

 

 

 

 

 

 

Common Stock:

 

 

 

 

 

 

No par value; 55,000,000 shares authorized 33,196,404 and 33,008,185 issued and outstanding at September 30, 2022 and December 31, 2021, respectively

 

 

119,801

 

 

 

118,646

 

Paid-in capital

 

 

5,477

 

 

 

5,866

 

Accumulated other comprehensive loss

 

 

(96,051

)

 

 

(36,922

)

Accumulated earnings

 

 

594,862

 

 

 

566,216

 

Total shareholders’ equity

 

 

624,089

 

 

 

653,806

 

Total liabilities and shareholders’ equity

 

$

1,241,333

 

 

$

935,343

 

 

 

 


 

img17760854_0.jpg 

img17760854_1.jpg 

 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

 

 

2022

 

 

2021

 

Operating Activities:

 

 

 

 

 

 

Net income

 

$

28,646

 

 

$

73,386

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

30,470

 

 

 

29,430

 

Deferred income taxes

 

 

(1,207

)

 

 

3,867

 

Non-cash stock based compensation

 

 

3,383

 

 

 

11,760

 

Loss on disposition of property and equipment

 

 

620

 

 

 

638

 

Other

 

 

881

 

 

 

(650

)

Changes in assets and liabilities:

 

 

 

 

 

 

Accounts receivable, net

 

 

(55,780

)

 

 

26,162

 

Inventory

 

 

(48,930

)

 

 

(34,019

)

Other assets

 

 

(10,868

)

 

 

597

 

Accounts payable

 

 

60,983

 

 

 

9,231

 

Other liabilities

 

 

4,759

 

 

 

(3,296

)

Net cash provided by operating activities

 

 

12,957

 

 

 

117,106

 

Investing Activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(25,737

)

 

 

(29,585

)

Proceeds from the sale of property and equipment

 

 

175

 

 

 

11

 

Acquisition of businesses, net of cash acquired

 

 

(224,097

)

 

 

(2,827

)

Proceeds from deferred purchase price of factored receivables

 

 

2,168

 

 

 

 

Cost of technology investments

 

 

(350

)

 

 

(7,557

)

Net cash used in investing activities

 

 

(247,841

)

 

 

(39,958

)

Financing Activities:

 

 

 

 

 

 

Borrowings on debt

 

 

207,000

 

 

 

 

Repayments of debt

 

 

(11,559

)

 

 

(151,993

)

Proceeds from the exercise of Common Stock options

 

 

1,556

 

 

 

7,467

 

Taxes withheld and paid on employees' share-based payment awards

 

 

(5,415

)

 

 

(3,991

)

Acquisition contingent consideration payment

 

 

 

 

 

(69

)

Net cash provided by (used in) financing activities

 

 

191,582

 

 

 

(148,586

)

Foreign currency effect

 

 

(8,141

)

 

 

(1,821

)

Net decrease in cash and cash equivalents

 

 

(51,443

)

 

 

(73,259

)

Cash and cash equivalents at beginning of period

 

 

190,606

 

 

 

268,345

 

Cash and cash equivalents at end of period

 

$

139,163

 

 

$

195,086

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

Cash paid for taxes

 

$

13,509

 

 

$

12,348

 

Cash paid for interest

 

$

3,334

 

 

$

1,823